---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 264
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody against the RSV F glycoprotein, used to prevent respiratory syncytial virus (RSV) infection in high-risk infants by neutralizing the virus and blocking cell entry.
The TxGNN model predicts it may be effective for **Benign Neoplasm of Tongue**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the evidence pack itself flags it as a likely false positive.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV (呼吸道融合病毒) 感染預防 |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| New Zealand Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed formal mechanism-of-action (MOA) data is marked as a data gap in this evidence pack. However, the model's own rationale text describes palivizumab's known mechanism: it is a monoclonal antibody that binds the RSV fusion (F) glycoprotein and neutralizes the virus, blocking its entry into respiratory epithelial cells. This is a purely antiviral mechanism with no known antineoplastic, antiproliferative, or tissue-remodeling activity.

There is no plausible biological link between RSV neutralization and the pathophysiology of a benign tongue neoplasm (localized epithelial/connective tissue proliferation). The evidence pack explicitly flags this concern: all 10 top-ranked predicted indications for this drug cluster tightly around a score of ~0.9994 (ranks 871–917) and are almost entirely unrelated tumor/cyst entities across disparate anatomic sites and cell lineages (tongue, epiglottis, testis, jugular foramen schwannoma, thyroglossal duct cyst, etc.). This tight score clustering across mechanistically unrelated diseases is a strong signature of a knowledge-graph embedding artifact rather than a genuine pharmacological signal.

Given the absence of any supporting clinical trial or literature evidence, and the mechanistic implausibility, this prediction should be treated as low-confidence and likely spurious rather than a genuine repurposing lead.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## New Zealand Market Information

Palivizumab currently has no market authorizations on record (market status: 未上市 / not marketed, 0 licenses).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no clinical trial or literature support (Evidence Level L5), no plausible mechanistic link between RSV neutralization and tumor pathophysiology, and shows a score-clustering pattern across 10 unrelated diseases that strongly suggests a model artifact rather than a true signal.

**To proceed, the following is needed:**
- TFDA/package insert safety data (currently Blocking data gap — required before any S1 safety screening)
- Formal DrugBank MOA confirmation (currently High-severity data gap)
- Independent investigation into why this drug's top predictions cluster at near-identical scores across mechanistically unrelated oncology indications, to rule out a systematic model artifact before evaluating any individual prediction in this batch
- Preclinical or mechanistic rationale specifically connecting RSV F-protein neutralization to tongue neoplasm biology, if this candidate is to be pursued further
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

